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Abstract
Background: Molecular iodine (I2) exhibits antiproliferative and apoptotic effects on in vivo and in vitro cancer
models. These effects are thought to be mediated by an iodinated arachidonic acid derivative, 6-iodolactone (6IL),
and one of the proposed mechanisms is that 6IL activates Peroxisome Proliferator-Activated Receptors type gamma
(PPARG). These receptors have been implicated in the inhibition of carcinogenic processes, in addition to their
classical role in maintaining lipid and glucose homeostasis. The aim of this study was to determine whether PPARG
participates in the 6IL antiproliferative and apoptotic effects on the mammary cancer cell line MCF-7.
Methods: The 6IL/PPARG complex was inhibited by the PPARG antagonist GW9662, in both an endogenous and
overexpressed (adenoviral vector infection) context, and stable PPARG-knockdown MCF-7 cells (RNA interference,
confirmed with hydrolysis probes and Western blot), were used to corroborate the PPARG participation. 6IL effects
on proliferation (measured by Trypan Blue exclusion) and apoptosis (phosphatidylserine identification by flow
cytometer) were evaluated in conditions of chemical inhibition (GW9662) and silencing (RNA interference). A
wound-healing assay was conducted on wild-type and stable PPARG-knockdown MCF-7 cells to evaluate the
antimigrational effect of 6IL. Caspase-8 activity was evaluated to determine if the extrinsic pathway is involved in
the effects of 6IL and I2 treatment.
Results: Antiproliferative and pro-apoptotic 6IL effects require the activation of PPARG. In addition, wound-healing
assays show that 6IL is able to inhibit MCF-7 cell migration and that PPARG plays a role in this phenomenon.
Finally, the data exclude the participation of the extrinsic apoptotic pathway in 6IL- and I2-induced apoptosis.
Conclusions: These results support the previously proposed mechanism, in which the I2 effects are mediated by
6IL, and they provide further support for the use of I2 as coadjuvant in breast cancer treatment.
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Background
6-Iodo-5-hydroxy-8,11,14-eicosatrienoic acid, δ-lactone
(6-iodolactone or 6IL) is an iodinated arachidonic acid
(AA) derivative and has been proposed to mediate the
antitumoral effects of iodine [1–3]. Molecular iodine (I2),
but not iodide (I−), exerts antineoplastic actions on diverse
tissues (mammary, prostate and thyroid glands, and on
melanoma, pancreas carcinoma and neuroblastoma cell
lines), and various studies suggest that these effects can
involve direct or indirect mechanisms [4–8]. In the direct
effect, the oxidant/antioxidant property of I2 can dis-
rupt the mitochondrial membrane potential and trigger
mitochondrion-mediated apoptosis [6, 9]; on the other
hand, the indirect path involves the generation of iodolipid
intermediates, and there is evidence that 6IL could be one
such intermediate. The presence of 6IL has been reported
in normal and tumoral mammary gland from rats with
continuous I2 supplements in their diet [2]. 6IL has also
been observed in an in vitro model, in which an iodin-
ated lipid co-migrating with the 6IL standard was de-
tected in 125I2-treated MCF-7 cells [5].
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At the molecular level, both I2 as 6IL generate antitu-
mor effects through similar pathways. Both trigger a p53/
p21-mediated cell growth arrest, and both induce Bax-
caspases and AIF/PARP-1 apoptosis [1, 9]. In MCF-7
cells, 6IL supplement is accompanied by a significant
stimulation of peroxisome proliferator-activated re-
ceptor type gamma (PPARG) and inhibition of PPAR
alpha (PPARA) expression [10]. Moreover, using electro-
phoretic mobility shift assays (EMSAs), these authors
demonstrated that 6IL is a PPAR ligand and can activate
the PPAR response element (PPRE) (as shown by reporter
gene transactivation assays). PPARs are involved in lipid
metabolism, energy homeostasis and differentiation, and
they have also been associated with positive or negative
effects on carcinogenesis of various neoplasias [11–13].
While PPARA has been linked to carcinogenesis promotion
[14, 15], PPARG or NR1C3 [16, 17] is proposed to be an
antineoplastic agent, since it inhibits proliferation, induces
apoptosis and promotes differentiation [18–22]. These
opposing effects of PPARA and PPARG have been docu-
mented in normal and tumoral breast tissue and mammary
cell lines [23, 24]. With respect to differentiation, 6IL
induces cytoplasmic accumulation of lipid droplets, in
a way comparable to that of the synthetic PPARG agon-
ist rosiglitazone [10]. Thus, while previous work has
shown a close relationship between PPARG and 6IL, here
we use chemical and molecular approaches to demonstrate
that the 6IL/PPARG complex is an intermediary in the anti-
proliferative and apoptotic effects of molecular iodine.
Results
GW9662 cancels the apoptotic and antiproliferative
effects of 6IL
To demonstrate that PPARG activation plays a key role in
the 6IL effects, we inhibited PPARG/6IL complex forma-
tion by blocking the PPARG ligand-binding domain with
its highly specific antagonist GW9662. To determine the
appropriate concentration of GW9662, i.e., a concentration
that inhibited PPARG/6IL complex formation without
causing the antiproliferative effects previously reported
[25], we performed a dose–response curve (0.2 to 10 μM)
for GW9662 in MCF-7 cells (Fig. 1a), and selected 0.5 μM
Fig. 1 Antiproliferative and apoptotic effect of 6IL is blocked by GW9662 (GW). a MCF-7 cells were treated with increasing GW9662 concentrations to
determine the optimal concentration that did not inhibit proliferation; 0.5 μM was selected for use in subsequent experiments. b Proliferation in the
presence of 10 μM 6IL and after GW pretreatment was analyzed by the Trypan Blue exclusion assay. c Apoptosis was analyzed by flow cytometry (c, d).
Results are expressed as percent change with respect to the control. Data are expressed as mean ± SD (n = 4 independent assays), and the
asterisk indicates a significant difference with respect to the control (P < 0.05)
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for further experiments. Figure 1b shows that the 6IL sup-
plement exerted a significant antiproliferative effect, which
was prevented when the cells were pre-incubated (2 h)
with GW9662. The 6IL treatment induced a significant,
nearly two-fold increase in the apoptotic population com-
pared to the control level (Fig. 1c-d), and this effect was
blocked when the cells were pretreated with GW9662.
Overexpression of PPARG enhances the antiproliferative
and apoptotic effects of 6IL
Figure 2a and b show the infection efficiency of MCF-7
with the GFP- and PPARG-adenoviral vectors, as mea-
sured by GFP intensity and mRNA amplification, re-
spectively. Figure 2c shows the proliferation rate with
ascending MOI (details in methods section), and a MOI
Fig. 2 Overexpression of PPARG enhances antiproliferative and apoptotic effects of 6IL, and these enhancements are partially prevented by
GW9662 (GW). a Representative panels of the infection-efficiency assay. MCF-7 cells were infected (24 h) with AdGFP at increasing multiplicities of
infection (MOIs). GFP expression is reported as a percentage of the number of events (%). b PPARG expression in AdPPARG-infected cells was analyzed
by qPCR and normalized to ACTB expression. c A range of MOIs was analyzed to determine the optimal level with no effect on proliferation; an MOI of
50 was selected for subsequent experiments. d Fatty acid synthase (FASN) expression was analyzed by the qPCR assay, and the results were normalized
to ACTB expression. e Proliferation in the presence of 10 μM 6IL and after GW pretreatment was analyzed by the Trypan Blue exclusion assay. f The
apoptotic effect of 6IL was analyzed by flow cytometry, and the results are expressed as percent change with respect to the control. Data are expressed
as mean ± SD (n = 4 independent assays); the asterisks indicate significant differences with respect to the control (P < 0.05), and different letters indicate
significant differences between groups (P < 0.05)
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of 50 was chosen for further experiments. Functional
PPARG overexpression was confirmed by fatty acid
synthase (FASN) expression, a PPARG-regulated gene
(Fig. 2d). Figure 2e shows that the antiproliferative
effect of the 6IL supplement was significantly inten-
sified in the AdPPARG-infected group compared to
the uninfected group, and that preincubation with
GW9662 only partially prevented this pronounced
effect. In contrast, the overexpression of PPARG in-
creased the sensitivity of these cells to the apoptotic
effect of 6IL, and this effect was strongly inhibited
by GW9662 (Fig. 2f ).
The silencing of PPARG expression blocks the
antiproliferative and apoptotic effects of 6IL
To confirm the stable transfection of RNAi against
PPARG mRNA in selected cells, GFP expression (from
the GFP gene co-inserted with the RNAi into the
HuSH™ plasmid) was assessed (Fig. 3a). PPARG silencing
was confirmed by qPCR with specific Hydrolysis Probes
(Fig. 3b and Table 1) and Western blot (Fig. 3c). Wild
type (WT), Scramble-PPARG (Scramble) and RNAi-
PPARG (RNAi) MCF-7 cells were treated with 10 μM
6IL over a 96-h period, and their proliferation rates were
evaluated. Figure 3d shows that WT and Scramble-
Fig. 3 Knockdown of PPARG blocks the 6IL effects. MCF-7 cells were transfected with a retroviral silencing plasmid (HuSH™) containing a short,
specific hairpin with RNA interference against PPARG (RNAi) or containing a scramble sequence (Scramble). a Representative microphotographs of
GFP expression in stably transfected MCF-7 cells (20× objective, scale bar 50 μm). b PPARG expression was analyzed by qPCR and normalized to
ACTB expression. c PPARG protein was quantified by Western blot and densitometry and is reported as percent change with respect to wild-type
(WT) cells. d Proliferation in the presence of 10 μM 6IL was analyzed by Trypan Blue exclusion. e The apoptotic effect of 6IL was analyzed by flow
cytometry, and the results are expressed as percent change with respect to the corresponding control. Data are expressed as mean ± SD (n = 4
independent assays), and different letters indicate significant differences between groups (P < 0.05)
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PPARG MCF-7 cells had the same proliferation rates,
whereas RNAi-PPARG MCF-7 cells exhibited signifi-
cantly faster proliferation. The 6IL supplement inhibited
proliferation of WT and Scramble-PPARG MCF-7 cells,
whereas it had no effect on the PPARG-knockdown
group (RNAi-PPARG). Figure 3e summarizes the apop-
totic effect of 6IL in these groups, showing significant
apoptosis on WT and Scramble-PPARG cells and no ef-
fect on RNAi-PPARG MCF-7 cells.
6IL inhibits MCF-7 cell migration, but this effect is blocked
by silencing PPARG
Groups were treated for 24 h with 10 μM 6IL or ve-
hicle, and the migration rate was evaluated by a
wound-healing assay (Fig. 4a). WT and Scramble-
PPARG MCF-7 cells treated with 6IL showed signifi-
cant inhibition of migration, around 60 %; however,
6IL did not change the migration rate of RNAi-
PPARG MCF-7 cells (Fig. 4b).
Table 1 Real-time PCR primer sequences
Gene Sequence (5′–3′) Annealing temp (°C) ID
FASN Sense GGAATGGGAAGACACCTATGGA 62 GenBank NM_004104.4
Antisense AGAGAGAGCTCAGATACGTTGAC
PPARG Sense TCTCTCCGTAATGGAAGACC 62 GenBank L40904.2
Antisense GCATTATGAGACATCCCCAC
ACTB Sense CCATCATGAAGTGTGACGTTG 62 GenBank NM_001101.3
Antisense ACAGAGTACTTGCGCTCAGGA
PPARG Hydrolysis Probe Sense GATGTCTCATAATGCCATCAGGTT 60 RTPrimerDB ID: 5471
Antisense GGATTCAGCTGGTCGATATCACT
Probe CCAACAGCTTCTCCTTCTCGGCCTG
ACTB Hydrolysis Probe Sense TCCTTCCTGGGCATGGAG 60 RTPrimerDB ID: 2418
Antisense AGGAGGAGCAATGATCTTGATCTT
Probe CCTGTGGCATCCACGAAACTACCTTC
Fig. 4 6IL inhibits MCF-7 migration and this effect is partially reverted by PPARG knockdown. Wild type, Scramble- and RNAi-PPARG transfected MCF-7
cells were treated with 10 μM 6IL for 24 h, and the number of cells that had migrated into the scratch during this time was determined (10× objective,
scale bar 200 μm, average scratch width 377 μm). a Representative microphotographs of wound-healing assays. b Migrating cells (total number). Data
are expressed as mean ± SD (n = 3 independent assays), two-way ANOVA and Tukey’s multiple comparison tests were performed; different
letters indicate significant differences between groups (P < 0.05)
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The 6IL induction of apoptosis is not activated by the
extrinsic pathway
To evaluate the participation of the extrinsic pathway in
the 6IL or I2 effects on apoptosis, caspase-8 activity was
evaluated. Neither 10 μM 6IL nor 200 μM I2 treatments
produced any change in caspase-8 activity (Fig. 5).
Discussion
A significant body of data from in vivo experiments
[4, 26–29], clinical trials [30–33], and epidemiological
reviews [34–36] support the notion that molecular
iodine has a protective effect against the progression
of neoplastic diseases and inflammatory/proliferative
pathologies. An important fact to consider is that
these beneficial effects occur only at relatively high
iodine concentrations (milligrams/day) and only in
those tissues that are able to capture iodine. In the
case of mammary and prostate glands, both normal
and tumoral cells internalize I2 by a sodium/iodine sym-
porter (NIS)-independent mechanism [1, 4, 5, 8, 37] that
seems to involve a facilitated diffusion process (saturable
and dependent on protein synthesis) [5]. It has not yet
been determined how I2 reacts with cell components, but
I2 is known to bind covalently to proteins and lipids [5].
The iodination of fatty acids generates several derivatives,
but those from arachidonic acid (AA), like 6IL, are espe-
cially relevant since endogenous 6IL has been detected
[38, 39], and it generates a range of biological effects [3].
The proposal that PPARG plays a role in the antitumor ef-
fects exhibited by I2 after its conversion to 6IL is sup-
ported by the following evidence: 1) 6IL can be identified
in both in vitro and in vivo models after administration of
I2 [1, 2]; 2) expression of PPARG is increased in I2- or 6IL-
supplemented conditions (possibly through an autoregula-
tion mechanism) [2, 10]; 3) the antiproliferative effect of I2
is only observed in cancer cells, which contain elevated
concentrations of AA [2]; and 4) when incubated with
total protein, 6IL can activate the PPAR response element
(shown by luciferase transactivation assays) and is capable
of inducing MCF-7 cells to accumulate lipid droplets in
the same manner as the highly specific agonist rosiglita-
zone [10]. Previously, our group showed that the molecu-
lar antiproliferative/apoptotic actions of the 6IL/PPARG
complex include the activation of p53 and the consequent
increase of p21 expression, thereby inducing cell arrest
and Bax-caspase expression, which activates the intrinsic
apoptosis pathway [1, 28, 29]. GW9662 irreversibly modi-
fies Cys285 in the PPARG ligand-binding domain with an
IC50 in the nanomolar range [40], as compared to the mi-
cromolar IC50 of 6IL [1, 10]. This very high affinity can ex-
plain the almost complete inhibition by GW9662
observed in control cells. However, proliferation was not
totally blocked in cells overexpressing PPARG. By its na-
ture, the adenoviral system forces the cell to maintain un-
regulated expression; therefore, it is possible that the
GW9662 concentration was not sufficient to saturate the
PPARGs due either to their overexpression from the vec-
tor or to well-established, positive, autoregulatory mecha-
nisms that maintain a high and continuous expression of
PPARG [41, 42]. In contrast, the 6IL-induced effect on
apoptosis is totally blocked by GW9662 in both control
and PPARG-overexpressing cells. Thus, partial PPARG
blockage may unmask this dual action of 6IL, in which
only a few free PPARG receptors are required for the anti-
proliferative effect (maybe cell cycle arrest), but additional
available receptors are needed to induce apoptosis. Similar
dose-dependent responses of PPARG ligands have been
described in the literature previously, showing induction
of arrest at low concentrations, whereas at high levels they
trigger apoptosis [43, 44]. Moreover and although molecu-
lar mechanisms for these preferential responses have not
been explored, differential recruitment of coactivator can-
not be excluded. More than 300 cofactors (coactivators,
coregulators, corepressors, etc.) have been identified for the
nuclear receptor family. It has been shown that these ele-
ments interact with one another and the same ligand mod-
ify transcription of many genes [45]. Interestingly, in the
PPARG-overexpressing cells, 6IL administration also in-
duces increased expression of FASN, a PPARG-regulated
gene that is related to differentiation [46, 47]. This observa-
tion is consistent with the differentiation effect of 6IL, ob-
served as lipid accumulation in MCF-7 cells [10].
Fig. 5 Extrinsic apoptotic pathway is not involved in the induction
of apoptosis by 6IL or I2. MCF-7 cells were treated with 10 μM 6IL or
100 μM I2 for 48 h. Caspase-8 activity was analyzed by a colorimetric
assay and normalized for the amount of protein. The results are
reported as percent change with respect to the control. Data are
expressed as mean ± SD (n = 3 independent assays). There were no
significant differences between groups
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In relation with silencing the expression of PPARG by
molecular tools, our results show that the proliferation
rate of RNAi-PPARG MCF-7 cells was two-fold greater
than that of MCF-7 control cells, corroborating similar
reports in other cancer cells [48]. The findings that
MCF-7 cells with PPARG knockdown are insensitive to
both the antiproliferative/apoptotic as well as to the
anti-migratory effects of 6IL are clear indications that
these receptors have an important role in the antineo-
plastic actions of I2 or 6IL. The next step is to determine
if 6IL affects the cell’s invasive characteristics, since the
activity of some metalloproteinases and other invasive
markers has been blocked by PPARG ligands in several
cancers [49, 50].
Finally, it has been described that I2 or 6IL induces
apoptosis effects through at least two pathways: AIF/
PARP1 and Bax-caspases [1, 9]; Bonofiglio et al. [51] re-
ports that PPARG is able to activate the promoter of the
FasL gene, thereby inducing extrinsic apoptosis in MCF-
7 cells; this observation was reinforced recently by simi-
lar findings in human colorectal cancer cells [52]. In the
present work we explored if the extrinsic apoptotic path-
way is activated by the 6IL/PPARG complex. Our results
show that caspase-8 activity is not increased by I2 or by
6IL treatment; therefore, it seems that the apoptotic ef-
fects of I2 and 6IL are mediated exclusively by intrinsic
apoptosis pathways.
Conclusion
In summary, our data demonstrate that the antitumor
effects of 6IL are mediated by PPARG; moreover, the in-
duction of FASN expression strengthens previous obser-
vations that 6IL also exerts differentiating effects
(adipogenetic induction [10]). 6IL inhibits migration, an
effect that may involve PPARG activation. Additionally,
6IL-induced apoptosis does not involve an extrinsic apop-
totic pathway. Together, these data reinforce the notion
that 6IL is a mediator of I2 effects, and it strengthens the
proposal that I2 can be a useful coadjuvant in treatment of
cancer in tissues that take up iodine.
Methods
Materials and cell culture
Dulbecco’s modified Eagle’s medium (DMEM), fetal bo-
vine serum (FBS), penicillin/streptomycin, puromycin
and trypsin solution were supplied by GIBCO (Grand Is-
land, NY, USA). Arachidonic acid (AA) (purity >99 %)
was used to synthesize 6IL was from Calbiochem (La
Jolla, CA, USA). GW9662 (purity >98 %), a specific
PPARG antagonist, was obtained from Sigma-Aldrich
(St. Louis, MO, USA). All other chemicals were of the
highest grade of purity commercially available. The
breast cancer cell line MCF-7 was obtained from ATCC®.
The cells were maintained in Basal Medium (DMEM
supplemented with 10 % FBS, 100 U/mL penicillin,
100 μg/mL streptomycin) at 37 °C and 5 % CO2 prior to
experiments.
Chemical synthesis of 6IL
6IL was synthesized with a modification of the method
of Monteagudo [53]. Briefly, to a solution of AA (65 mg)
in acetonitrile (0.8 mL) was added a solution of iodine
(156 mg) in acetonitrile (8 mL) at 4 °C. The solution was
kept under N2, stirred for 4 h at room temperature and
protected from light. The solution containing crude
product was concentrated under low nitrogen flow to
0.5 ml and separated on preparative TLC using the solv-
ent system CH2Cl2/MeOH (97.5:2.5). The reaction prod-
ucts, AA (rf: 0.5) and 6IL (rf: 0.88) standards were
visualized by iodine vapors, and the 6IL synthesized was
eluted with the same solvent and concentrated under
low nitrogen flow.
Adenoviral infection
Recombinant adenoviruses expressing human PPARG
(AdPPARG) were provided by Dr. Steals (Institut Pasteur
de Lille, France). Adenovirus expressing GFP (AdGFP),
provided by Dr. Hernandez-Gutiérrez (Universidad
Panamericana, México), was used to confirm infection
and as control. Viruses were multiplied in HEK-293
cells (provided by Dr. Martínez-Torres, Instituto de
Neurobiología UNAM, México). Adenoviral titer was
determined by the MOI (multiplicity of infection) test
(AdEasy™ Vector System, application manual version
1.4). Prior to treatment with GW9662 and/or 6IL,
MCF-7 cells were infected at an MOI of 50 for 24 h in
basal medium.
Stable transfection with shRNA against PPARG
(RNAi-PPARG)
Retroviral silencing plasmid (HuSH™) containing a short,
specific hairpin with RNA interference for PPARG, a
puromycin resistance gene, a tGFP gene and a U6 pro-
moter was obtained from Origen Technologies, Inc.
(Rockville, MD, USA) (RNAi-PPARG cells). A similar
plasmid but with a scrambled sequence of the short
RNAi hairpin against PPARG (Scramble-PPARG cells)
was used as internal control. MCF-7 cells were trans-
fected with 5 μg of plasmid and Xfect™ Transfection
Reagent (Clontech Laboratories, Mountain View, CA,
USA) according to the manufacturer’s instructions, and
they were maintained in culture for 48 h; after this time
the transfected cells were selected with 1.0 μg/mL puro-
mycin daily over 2 weeks and expanded. Transfection of
the cells was confirmed by tGFP expression using an
IX50 Olympus microscope with inverted reflected light
fluorescence system (Olympus Inc., NY, USA), or by an
Agilent 2100 bioanalyzer using an On-Chip flow cytometry
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system (Agilent Technologies, USA). Knock-down of
PPARG expression was evaluated by quantitative real time
PCR (qPCR) with the specific Hydrolysis Probes (Sigma-
Aldrich Co., MO) shown in Table 1 and by Western Blot.
The selected and stably transfected population was main-
tained under “light pressure” (0.5 μg/mL puromycin) over
the course of the experiments.
Experimental groups
The experiments were carried out on AdPPARG-MCF-
7-infected cells, on Scrambled- or RNAi-PPARG-MCF-
7-transfected cells and on wild-type MCF-7 cells. The
cells were cultured at a density of 5 × 105 cells in 60-mm
culture dishes (Nalge Nunc International, Naperville, IL)
for qPCR assays; 4 × 104 cells/well in 24-well culture
plates for proliferation assays, 2 × 105 cells in 60-mm
culture dishes for apoptosis experiments, 3 × 106 cells in
100-mm culture dishes for Western blot assays, 8 × 105
cells in 60-mm culture dishes for wound-healing assays,
and 5 × 106 cells in 100-mm culture dishes for caspase-8
activity assays. All cells were seeded in complete basal
medium and incubated for 24 h before treatment; at the
beginning of experiments the medium was changed to
low serum (0.5 %)-containing medium. The cells were
treated for 24, 48, 72 or 96 h, (depending on the experi-
ment) at 37 °C with 10 μM 6IL, 0.5 μM GW9662 or ve-
hicle (ethanol) diluted before application in low serum-
containing medium. In the GW9662/6IL-treated group,
GW9662 was administered 2 h prior to 6IL treatment.
Quantitative PCR
Total RNA was extracted from cells using TRIzol® re-
agent (Life Technologies, Thermo Fischer Scientific,
MA, USA) according to the manufacturer’s instructions.
Two micrograms of total RNA was reversed transcribed
using the Superscript II system (Invitrogen, Carlsbad,
CA). qPCR was performed on the sequence detector sys-
tem Roto-Gene 3000 (Corbett Research, Mortlake,
Australia) using SYBR green as a marker for DNA amp-
lification. The reaction was performed with 1 μL cDNA
template and the Maxima SYBR Green/ROX qPCR Mas-
ter Mix (Thermo Fischer Scientific, MA), using 40 cycles
of three-step amplification (94 °C for 30 s, 55–62 °C for
30 s, 72 ° C for 30 s) and the gene-specific primers listed
in Table 1. PCR generated only the expected specific
amplicon, which was demonstrated in each case by the
melting temperature profile (dissociation curve) and by
electrophoresis of 5 μL of the PCR product through a
2 % agarose gel in TAE buffer then visualization by eth-
idium bromide. No PCR products were observed in the
absence of template. Gene expression was calculated
using the D cycle threshold method and normalized to
the content of ACTB, a non-regulated housekeeping
gene. All measurements were performed in triplicate.
Western blot
Pellets of whole protein were obtained from lysed cells
using RIPA buffer with complete Mini, EDTA-free prote-
ase inhibitor cocktail tablets (Roche Diagnostics GmbH,
Germany). The extracted proteins were quantified by the
Bradford method (Bio-Rad protein assay; Hercules, CA)
and analyzed by Western blot. SDS polyacrylamide gel
electrophoresis was performed as described [10], using
stacking and resolving gels (the latter with 15 % acryl-
amide). Samples containing 50 μg of protein were applied
to each lane. After electrophoresis, the proteins were elec-
trotransferred to a nitrocellulose membrane (Bio-Rad,
Germany), which was then blocked overnight with TBS
containing 5 % non-fat dry milk. The membranes were
rinsed and treated with polyclonal anti-PPARG antibody
(sc-7196, 57 kDa, 1:1000, Santa Cruz Biotechnology Inc.,
USA) and anti-ACTB (sc-1616, 43 kDa, 1:10,000, Santa
Cruz Biotechnology Inc.) as a protein-loading control.
Protein bands were visualized using a chemiluminescent
detection system (ECL, Amersham Biosciences, UK).
Densitometry was performed with Image Lab™ software
(Bio-Rad Laboratories, CA, USA), and chemiluminescence
was normalized to the level of ACTB protein.
Proliferation assays
The effects on proliferation of 10 μM 6IL, 0.5 μM
GW9662 and the GW9662/6IL mixture were analyzed
using the Trypan Blue dye-exclusion assay. The cells
(4 × 104/well) were cultured in DMEM supplemented
with 10 % FBS on 24-well culture plates. Control cells
were treated with 0.1 % ethanol (solvent for 6IL). After a
72-h treatment, the cells were harvested with trypsin-
EDTA 0.05 % (Life Technologies Brand of Thermo
Fischer Scientific, MA, USA). Trypan Blue (0.4 %) was
added; those cells that excluded the dye were counted
with a hemocytometer under the microscope (Leica
Inverted Microscope DMIL model, Germany); prolifera-
tion is reported as fold change with respect to control.
Apoptosis assays
Apoptosis was assessed by detecting phosphatidylserine
on the external surface of the cell membrane with
annexin V conjugated to the Cy5 fluorophore. To mark
cells with intact cell membranes, Calcein-AM was used.
Apoptosis was assessed by an Agilent Bioanalyzer 2100
and apoptosis kit following the manufacturer’s instruc-
tions (Agilent Technologies, USA). Briefly, after treat-
ment the cell density was adjusted to 1 × 106 per mL in
200 μL basal medium, and 200,000 cells were transferred
to a 1.5-mL microtube and centrifuged at 2500 rpm for
3 min; the supernatant was discarded. The pellet was re-
suspended in 200 μL of 1X Binding Buffer (provided by
the manufacturer), and 1 μL of Annexin V (Abcam®,
UK) was added and incubated at room temperature for
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10 min; after centrifugation at 2500 rpm for 3 min the
supernatant was removed, and 1 μL each of Calcein-AM
and Fluorolink Cy5 in 200 μL of Binding Buffer were
added to the pellet and incubated for 10 min. Finally,
the cells were collected by centrifugation and resus-
pended in Cell Buffer (provided by the manufacturer). A
10-μL aliquot of cells from each treatment was placed
on the cell fluorescence LabChip® together the solutions
provided in the kit. The apoptotic cells are reported as a
percentage of the number of events; this population is
delimited in a standardized region by the program Cell-
Chip Agilent 2100 Expert software (Agilent Technologies,
USA).
Wound-healing assay
RNAi-PPARG MCF-7 cells, Scramble-PPARG MCF-7
cells and wild-type MCF-7 cells, 8 × 105 in each case,
were seeded on 60-mm culture plates and incubated at
37 °C and 5 % CO2. After 24 h, the attached cells were
scratched three times in parallel with a 1000-μl pipette
tip (~377 μm) and treated with 10 μM 6IL or vehicle
(ethanol) for 24 h. After this time, three new parallel
wounds were performed as width control; the number of
migrating cells was obtained by counting the number of
cells inside this width control. The count was measured
by Leica Application Suite Version 2.8.1., and the images
were captured with a 10× objective lens using a Leica
DM 2500 microscope and DFC 420 camera (Leica
Microsystems, CMS GmbH, Germany). The results are
presented as number of migrating cells of treated (6IL)
vs. control (Ctrl) groups (mean ± SD). At least three
fields were analyzed for each plate, and each group was
analyzed in three independent experiments.
Caspase-8 activity assay
The caspase-8/FLICE activity was measured using a
commercial kit (ApoTarget, Invitrogen Co., CA, USA)
according to manufacturer’s instructions. Briefly, 5 × 106
MCF-7 cells were collected after a 48-h incubation with
I2 or 6IL. The cell pellet was lysed, and an aliquot con-
taining 200 μg of protein was incubated with DTT
(10 mM) and a colorimetric substrate, IETD-p-nitroani-
lide; (pNA, final concentration 200 μM) at 37 °C for
120 min in the dark. The samples were then read in the
spectrophotometer at 405 nm. The absorbance of pNA
from a treated sample was compared with an untreated
control to determine the fold increase in caspase-8 activity.
Statistical analysis
One- or two-way ANOVA was performed to determine
the significance of differences between groups, followed
by Tukey’s test for the significance of differences among
multiple experimental groups. Data are expressed as
mean ± standard deviation (SD), and values with P < 0.05
were considered statistically significant. In the figures,
an asterisk indicates significant differences with respect
to the control (P < 0.05), and different letters indicate
significant differences between groups (P < 0.05).
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